Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forma To Play To Its Strengths WIth Genentech Deal

This article was originally published in Start Up

Executive Summary

Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.

You may also be interested in...



Forma To Rev Its Discovery Engine For Deubiquitination

In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.

With Celgene Deal, Forma Makes First Foray Into Clinical Development

Forma Therapeutics has signed its largest and most ambitious oncology drug-discovery and development collaboration to date, in the exciting but early-stage area of protein homeostasis. Its new partner Celgene is no stranger to making big bets on promising cancer companies.

Project Sigma: Wellcome Funding For Scientific Research

The Wellcome Trust, the UK’s largest private funder of biomedical research, has hired industry veterans to run a new £200 million evergreen fund that will take full ownership of biotech start-ups and hold them with more patience than VCs can afford.

Related Content

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092143

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel